Conferences - Results from #500

Viewing 501-520 of 11879 articles

ASCO 2024: Development of a Machine Learning Model to Predict the Outcome of Randomized Clinical Trials of Patients with Metastatic Prostate Cancer

ASCO 2024: Zanzalintinib (XL092) plus Nivolumab in Non-Clear Cell Renal Cell Carcinoma: The Randomized Phase 3 STELLAR-304 Study

ASCO 2024: Biomarkers Associated with Outcomes from KEYLYNK-010: Pembrolizumab plus Olaparib Versus Next-Generation Hormonal Agent in Previously Treated Metastatic Castration-Resistant Prostate Cancer

ASCO 2024: Matching-Adjusted Indirect Comparisons of Talazoparib plus Enzalutamide Versus Olaparib plus Abiraterone and Prednisolone for First-Line Therapy in Patients with mCRPC and HRR Mutations/BRCAm

ASCO 2024: Comparative Effectiveness of First-Line Ipilimumab plus Nivolumab Versus Immune Checkpoint Inhibitors + Tyrosine Kinase Inhibitors in Patients with Intermediate or Poor Risk Metastatic Clear Cell Renal Cell Carcinoma

ASCO 2024: Race and Decisional Conflict About Genetic Testing in Patients with Advanced Prostate Cancer

ASCO 2024: Belzutifan in Patients with Advanced Clear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 2 LITESPARK-013 Study

ASCO 2024: Subcutaneous Nivolumab Versus Intravenous Nivolumab in Patients with Previously Treated Advanced or Metastatic Clear Cell Renal Cell Carcinoma: Safety and Patient-Reported Outcomes of the Randomized Phase 3 CheckMate 67T Trial

ASCO 2024: ODM-209, a CYP11A1 Inhibitor in Patients with mCRPC: Results from the STESIDES Phase 1 Study

ASCO 2024: EvoPAR-Prostate01: Phase III, Double-Blind, Placebo-Controlled, 2-Cohort, Randomized Study of Saruparib (AZD5305) in Combination with New Hormonal Agents in Patients with mCSPC with and Without Homologous Recombination Repair Mutation

ASCO 2024: CELC-G-201: A Phase 1/2, Open-Label, Randomized, Dose-Finding and Dose Expansion Study of Gedatolisib in Combination with Darolutamide in mCRPC

ASCO 2024: Independent Blinded Validation of an AI-Based Digital Histology Classifier for Prostate Cancer Recurrence and Metastasis Risk Prediction

ASCO 2024: Post-Progression Survival of Patients with mHSPC Who Received Darolutamide or Placebo: Post Hoc Analysis of ARASENS

ASCO 2024: ctDNA Fraction as a Predictor of Treatment Efficacy in a Randomized Phase 2 Trial of [177Lu] Lu-PSMA-617 Versus Cabazitaxel in mCRPC Progressing After Docetaxel

ASCO 2024: Enfortumab Vedotin with Pembrolizumab Versus Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma: Analysis of Cisplatin-Eligible Population from EV-302/KEYNOTE-A39

ASCO 2024: Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma (aUC): Long-Term Outcomes from JAVELIN Bladder 100 in Patients with Low Tumor Burden

ASCO 2024: ENLIGHTED Phase 3 Study: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy for Treatment of Low-Grade Upper Tract Urothelial Cancer

ASCO 2024: A Phase 1/2 Study of EG-70 (Detalimogene Voraplasmid) Intravesical Monotherapy for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

ASCO 2024: Rapid and Deep Prostate-Specific Antigen Response to Apalutamide plus ADT and Survival in Metastatic Castration-Sensitive Prostate Cancer in Real World Practice in the US (OASIS Project)

ASCO 2024: First-Line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma (RCC): An International Multi-Center Study

21
22
23
24
25
26
27
28
29
30